Vaxcyte, Inc.
PCVX · XNASCIK 1649094fmd_1BZE6F1FM1C3HWFT61G3P8JHDQManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2018 to Sep 30, 2026, 32 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Research and development | 30 | 46 | 74 | 78 | 169 | 332 | 477 | 794 |
| Total operating expenses | 36 | 54 | 90 | 104 | 232 | 468 | 570 | 924 |
| Operating income | (36) | (54) | (90) | (104) | (232) | (468) | (570) | (924) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – |
| Interest and investment income | 1 | 1 | 0 | 0 | 8 | 63 | 110 | 120 |
| Other non-operating income (expense) | 6 | 4 | 0 | 4 | 9 | 66 | 106 | 157 |
| Income tax expense | – | – | – | – | – | 0 | 0 | 0 |
| Net income | (29) | (50) | (89) | (100) | (223) | (402) | (464) | (767) |
| Net income to common shareholders | (29) | (50) | (89) | (100) | (223) | (402) | (464) | (767) |